Cingulate Inc. - CING STOCK NEWS

Welcome to our dedicated page for Cingulate news (Ticker: CING), a resource for investors and traders seeking the latest updates and insights on Cingulate stock.

Cingulate Inc. (NASDAQ: CING) is a clinical-stage biopharmaceutical company dedicated to improving patient outcomes through its proprietary Precision Timed Release™ (PTR™) drug delivery platform. Headquartered in Kansas City, Kansas, the company is focused on developing next-generation pharmaceutical products that address conditions requiring burdensome daily dosing regimens and that often yield suboptimal treatment outcomes.

Cingulate’s lead candidates target Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety disorders, with a particular emphasis on their flagship product, CTx-1301. CTx-1301 utilizes dexmethylphenidate, a compound approved by the FDA, to provide a rapid onset and entire active-day efficacy through three precisely timed medication releases. This approach aims to eliminate the need for booster doses and improve overall patient compliance and satisfaction. The product has already demonstrated significant promise in Phase 3 trials, with impressive clinical effect sizes that suggest broad potential impact.

Another key product in the pipeline is CTx-2103, a novel extended-release formulation of buspirone designed for the treatment of anxiety. CTx-2103 leverages the PTR platform to deliver three timed doses in one tablet, potentially offering substantial benefits over current multi-dose regimens. This product is currently progressing through clinical trials, with positive feedback from the FDA on its regulatory pathway.

In recent months, Cingulate has achieved several milestones: they announced successful Phase 3 trial data for CTx-1301, closed a $4 million public offering, and converted $5.8 million of debt into equity. These financial maneuvers have strengthened their balance sheet, enabling continued investment in their clinical programs. Additionally, Cingulate recently welcomed new executive leadership and independent directors, further fortifying their capabilities as they navigate the complexities of drug development and commercialization.

Cingulate is committed to ongoing research and development, leveraging its PTR platform not only for ADHD and anxiety but also exploring other therapeutic areas. This innovative platform integrates an Erosion Barrier Layer (EBL), which controls the drug release at precise times without premature release, enhancing the effectiveness and convenience of treatment.

For more information, visit their official website at Cingulate.com.

01/29/2024 08:00 AM

News

Longtime Cingulate Controller Jennifer Callahan Promoted to CFO

Rhea-AI Summary

Cingulate Inc. (NASDAQ: CING) has promoted Controller Jennifer Callahan to Chief Financial Officer, succeeding longtime CFO Lou Van Horn. The company aims to strengthen its balance sheet through traditional and non-dilutive transactions, with Callahan expressing excitement to lead the finance team into the future.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-11.59%

Tags

01/29/2024 06:45 AM

News

Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market

Rhea-AI Summary

Cingulate Inc. announced the conversion of $3.3 million of debt and accrued interest into equity by Werth Family Investment Associates, LLC, at a conversion price of $4.785 per share. The closing price of Cingulate’s common stock on Nasdaq on January 24, 2024, was $4.35 per share. WFIA also agreed to convert the remaining $3.0 million of principal under its outstanding note into pre-funded warrants to purchase 687,043 shares of Cingulate’s common stock. The offer and sale of the securities are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended, and Regulation D promulgated thereunder.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-11.59%

Tags

12/01/2023 09:00 AM

News

Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)

Rhea-AI Summary

Cingulate Inc. (NASDAQ: CING) has received guidance from the FDA to advance its investigational asset CTx-2103 for the treatment of anxiety into clinical development. The company plans to file an IND application in the first half of 2024 and design clinical studies for CTx-2103. This step may allow CTx-2103 to seek approval under the 505(b)(2) pathway, which typically requires less time and resources than the 505(b)(1) full NDA pathway. CTx-2103 is a once-daily, multi-dose tablet that provides three precisely timed doses of buspirone versus one immediate release dose, offering clear differentiation and compelling advantages over currently available treatment options.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2.39%

Tags

11/13/2023 04:15 PM

News

Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

Rhea-AI Summary

Cingulate Inc. (NASDAQ: CING) announced financial results for Q3 2023, including Phase 3 adult efficacy and safety trial data for CTx-1301, a $4M public offering, and $5.8M of debt converted into CING equity. The clinical update highlighted the positive results from the Phase 3 trial, with significant improvements in ADHD patients. The company also provided insights into its R&D expenses and net loss figures.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-3.23%

Tags

10/17/2023 02:22 PM

News

Cingulate to Host CNS Key Opinion Leader Panel in New York City

Rhea-AI Summary

Cingulate Inc. will be hosting a key opinion leader event on October 23, 2023, focused on their late-stage asset CTx-1301 in ADHD and anxiety-related disorders.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.96%

Tags

09/21/2023 11:23 AM

News

Cingulate Inc. To Present at the LD Micro Main Event XVI

Rhea-AI Summary

Cingulate Inc. to present at LD Micro Main Event XVI on October 4th.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.88%

Tags

09/13/2023 04:15 PM

News

Cingulate Announces Closing of $4.0 Million Public Offering

Rhea-AI Summary

Cingulate Inc. closes public offering, raising approximately $4.0 million for research and development and commercialization activities of its lead candidate CTx-1301.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

5.32%

Tags

09/11/2023 09:22 AM

News

Cingulate Announces Pricing of $4.0 Million Public Offering

Rhea-AI Summary

Cingulate Inc. announces pricing of public offering, expecting gross proceeds of approximately $4.0 million. The funds will be used for research and development, commercialization activities, and general corporate purposes.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.87%

Tags

09/11/2023 06:00 AM

News

Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

Rhea-AI Summary

CTx-1301 demonstrated clinically meaningful improvements in PERMP and CGI-S scores, with trend towards significance treatment effect size of 1.41 and 0.98 observed at 30 minutes and at hour 16, respectively. CTx-1301 showed a favorable safety profile compared to placebo. No patients reported experiencing insomnia during the randomized period.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.87%

Tags

09/08/2023 04:31 PM

News

Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium

Rhea-AI Summary

Cingulate Inc. announces debt conversion of $5.8 million into equity, following a $1.0 million capital investment in August 2023.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.87%

Tags

FAQ

What is the current stock price of Cingulate (CING)?

The current stock price of Cingulate (CING) is $4.65 as of November 21, 2024.

What is the market cap of Cingulate (CING)?

The market cap of Cingulate (CING) is approximately 14.9M.

What does Cingulate Inc. specialize in?

Cingulate Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation pharmaceutical products using its proprietary Precision Timed Release™ (PTR™) drug delivery platform. Their primary focus is on the treatment of ADHD and anxiety disorders.

What is CTx-1301?

CTx-1301 is Cingulate's lead product candidate for the treatment of ADHD. It utilizes the PTR drug delivery platform to release dexmethylphenidate in three precisely timed doses, providing rapid onset and entire active-day efficacy.

What recent financial achievements has Cingulate accomplished?

In recent months, Cingulate closed a $4 million public offering, converted $5.8 million of debt into equity, and raised over $17 million in capital, strengthening its financial position to support ongoing clinical development.

What is the Precision Timed Release™ (PTR™) platform?

The PTR platform is Cingulate's proprietary drug delivery technology designed to provide controlled release of active pharmaceutical ingredients at pre-defined times, enhancing medication efficacy and patient compliance.

How does CTx-2103 differ from other anxiety treatments?

CTx-2103 is a once-daily, multi-dose tablet that releases buspirone hydrochloride in three timed doses using the PTR platform, potentially offering significant advantages over current multi-dose regimens for anxiety treatment.

What was the outcome of the Phase 3 trial for CTx-1301?

The Phase 3 trial for CTx-1301 demonstrated a significant effect size, providing rapid onset and whole-day efficacy for ADHD treatment. The data supports its potential to offer substantial benefits to ADHD patients.

What is CTx-2103 being developed for?

CTx-2103 is being developed for the treatment of anxiety and anxiety-related disorders. It is designed to offer once-daily dosing with three precisely timed releases of buspirone hydrochloride.

What distinguishes Cingulate Inc. from other biopharmaceutical companies?

Cingulate distinguishes itself through its innovative PTR drug delivery platform, which aims to improve patient outcomes by providing controlled, precisely timed drug release, addressing the challenges of burdensome daily dosing regimens.